As artificial intelligence (AI) redefines the modern medical paradigm, South Korea has set another milestone in the field of medical AI. Recently, the Ministry of Food and Drug Safety (MFDS) of South Korea granted the world's first approval for a digital medical device based on generative AI technology. This not only marks a significant turning point in the history of medical device regulation but also strongly suggests South Korea's potential to play a leading role in the global AI healthcare market. AIRead-CXR, developed by domestic startup Soombit AI, is software that analyzes chest X-ray images to detect 57 types of abnormal findings and, based on these, generates text-based preliminary reports at a specialist level. Unlike existing AI-based medical devices, it possesses a fundamental differentiation by not merely visually indicating abnormal areas or quantifying severity, but by directly supporting clinical judgment with text. AIRead-CXR has now received Class III medical device approval from the MFDS, enabling its full-scale utilization in clinical settings. Notably, other major regulatory bodies, including the U.S. Food and Drug Administration (FDA), continue to maintain a cautious stance due to safety concerns surrounding this technology. As of April 2026, the FDA has approved over 1,450 AI and machine learning-based medical devices, but there has not been a single instance of generative AI, such as large language models (LLMs), being authorized for direct clinical decision support. This demonstrates that even the FDA, which leads the global medical AI market, holds an extremely conservative position on approving generative AI medical devices. The primary reason advanced regulatory authorities, including the FDA, hesitate to approve generative AI is its unique 'hallucination' phenomenon and the non-deterministic nature that can lead to varying results each time. 'Hallucination' refers to the phenomenon where generative AI models produce irrelevant or inaccurate outputs unrelated to the requested information. The main concern is the difficulty in objectively evaluating the safety of AI that freely generates text within the traditional review framework, which requires demonstrating equivalence with existing devices. Existing regulatory systems face fundamental difficulties in clearly identifying these issues and establishing systematic safety evaluation criteria. In contrast, the South Korean government has proactively introduced laws and guidelines to address this, responding swiftly. The secret to South Korea's ability to overcome these conservative regulatory barriers first lies in its 'proactive institutional overhaul'. Last year, with the enforcement of the 'Digital Medical Products Act,' the MFDS globally unveiled the 'Generative AI Medical Device Approval and Review Guidelines,' presenting new standards for safety and efficacy evaluation. By proactively providing tailored guidelines from clinical trial design to approval criteria, the regulatory authority offered clear directions to domestic companies, significantly reducing regulatory uncertainty and helping them secure key competitiveness in the global market. This regulatory innovation by South Korea is highly significant, as it leaves an unprecedented leading example in the history of global medical device regulation, extending beyond a single nation's case. Traditionally, medical device regulation has been led by the United States and Europe, with other countries tending to follow their standards. However, in the new technological domain of generative AI, South Korea has paved the way first, and this is expected to significantly influence the formation of future global regulatory standards. South Korea's Regulatory Innovation and Challenges Beyond 'Hallucination' From a global market perspective, this move signals a game-changer for the AI healthcare industry. The AI healthcare market is growing rapidly worldwide, and leading regulation in such a high-growth potential market offers not only technological innovation but also the opportunity to establish oneself as a market 'rule maker.' This approval is expected to be a crucial turning point for South Korea to emerge as a global 'rule maker' in the AI healthcare sector. Furthermore, South Korea's case is highly likely to serve as an important precedent for other countries in reviewing similar technologies. Of course, such pioneering efforts do not always guarantee a smooth path. Many experts express cautious optimism regarding this approval. It is pointed out that continuous risk assessment and management are essential as clinical data accumulates, given that the safety of generative AI cannot be perfectly guaranteed. While South Korea's case is indeed regarded as an innovative attempt, thorough monitoring systems and transparent disclosure of relevant data are crucial for such new technologies to be safely and effectively implemented in clinical practice. Specifically, systems must be esta
Related Articles